Prosensa and TREAT-NMD enter into strategic collaboration for PRO-051 clinical trial planning

Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, announces the successful completion of a feasibility enquiry using the TREAT-NMD Global Database for DMD and the TREAT-NMD Care and Trial Sites Registry for the planning of the phase II/III study for its lead compound PRO-051. For more detailed information, please click here.